CHAPTER 3: Classification and coding

Jacques Ferlay, Klaus Kraywinkel, Brian Rous and Ariana Znaor

The Cancer Incidence in Five Continents (CI5) series has followed the evolution of the International Classification of Diseases (ICD) through four revisions, from the seventh revision (ICD 7) to the tenth (ICD 10), and the creation of a coding scheme for oncology: the International Classification of Diseases for Oncology (ICD O) (WHO, 1976), now in its third edition (ICD-O-3) (Fritz et al., 2000), which is available from CI5 Volumes I (Doll et al., 1966) and II (Doll et al., 1970) presented data on cancer incidence coded to ICD-7 (WHO, 1957). Volume III (Waterhouse et al., 1976) published data using both ICD-7 and ICD-8 (WHO, 1967). ICD-8, which came into effect in 1968, was also used in Volume IV (Waterhouse et al., 1982). ICD-9 (WHO, 1977) was used for Volumes V (Muir et al., 1987), VI (Parkin et al., 1992), and VII (Parkin et al., 1997). ICD-10 (WHO, 1992) was used for Volumes VIII (Parkin et al., 2002), IX (Curado et al., 2007), and X (Forman et al., 2014).
The updates to ICD-10 (version 2010 available from and the 2011 revision of ICD-O-3 (WHO, 2013; available from were considered in this volume, which presents data for the 5 year period of 2008–2012. The data are published at the level of the three-character ICD-10 codes in the individual registry tables. The groupings of ICD codes adopted in the previous three volumes have been used again in this volume to maintain comparability over time. Table 3.1 presents the individual ICD-10 site codes, the full ICD-10 titles, the Volume XI groupings, and the short titles used in the tables of incidence.

Updates of ICD-10 and ICD-O-3
The update of ICD-10 introduced in 2010 resulted in changes for the neoplasm chapter which affected the “Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue (C81-C96)” group. Mainly, a new 3-digit category C86 “Other specified types of T/NK-cell lymphoma” and several new 4-digit codes were added to the existing ones, and in particular the new code C88.4 “Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], lymphoma of skin-associated lymphoid tissue (SALT-lymphoma) and lymphoma of bronchial-associated lymphoid tissue (BALT-lymphoma)”. These diagnoses were previously included within the ICD-10 (1990) C82.7 category in Volume X.
The 2011 revision of ICD-O-3 affected the morphology numerical list only, introducing new terms that have appeared in the recent literature particularly in the lymphoma and leukaemia group. Therefore, a new conversion table from ICD-O-3 first revision (2011) to ICD-10 (2010 version) for the ICD-O-3 morphology codes 9590/3 to 9992/3 had to be developed (see Table 3.2).

Classifications used in the cancer registry
Data submitted for the first four volumes of CI5 were sent in tabular format – organized by sex, site, and 5-year age group – on tape, diskette, or (most commonly) forms specifically designed for the purpose. The only verification possible was to tally the columns and rows. For Volume V, registries were given the option of sending data in the form of a case listing coded to ICD-9 topography only, or to ICD-9 or ICD-O topography plus ICD-O morphology. Only a very small minority of registries sent data coded to ICD-O. Contributors to Volume VI were encouraged to send data as a listing of individual cases, but 24% still sent tabulated data. Starting from Volume VII, data had to be sent as a listing of individual cases. Since the publication in 1976 of the first edition of ICD-O – which clearly defined axes of anatomical location, histology, and behaviour – international conformity to standard classification systems and coding rules has increased steadily. For data published in Volume IV (1973–1977), 90% of registries recorded histological diagnosis. For coding, just over a third of the registries used the American Cancer Society’s Manual of Tumor Nomenclature and Coding (MOTNAC) (ACS, 1951; 1968), a third had started to use ICD-O, and 12% used the Systematized Nomenclature of Pathology (SNOP) (CAP, 1965). About 75% of contributors to Volume V used ICD-O to code histology, and that proportion rose to more than 90% for Volumes VI and VII. Only 4 of the 186 contributors to Volume VIII, 1 of the 225 contributors to Volume IX, 2 of the 290 contributors to Volume X and all contributors to the present volume coded their histological data to ICD-O. Although most of the data submitted for this volume had been coded or converted to ICD-O-3 (see Chapter 6), registries were also asked what classification systems were used for coding data in the registry during the period. Of the 343 contributors, 326 registries (95%) coded to ICD-O topography and morphology (of which 319 used ICD-O-3), 17 registries (5%) coded to ICD-10 topography and ICD-O morphology.

All data supplied for this volume either were already coded to ICD-O-3 when submitted, or were converted by IARC to ICD-O-3 for checking, and were then converted to ICD-10 for presentation (see Chapter 6). This process ensures that the same validity checks and multiple primary rules are applied to all data, and that the final ICD-10 codes used in this publication follow a standard ICD-O-3 to ICD-10 (2010 version) conversion. When a dataset included an ICD-10 code, this was ignored in the tabulations. The ICD-O-3 to ICD-10 conversion program was written at IARC using the rules of the ICD-O-2 to ICD-10 conversion program developed by Percy (1998). The conversions strictly follow the ICD 10 coding rules, as expressed in the instruction manual of ICD-10 Volume 2 (Percy et al., 1990) or in the alphabetical index of ICD-10 Volume 3. For example, the combination of unknown primary site (ICD-O-3 topography C80.9) and fibrosarcoma, not otherwise specified (NOS; ICD-O-3 morphology 8810/3) is converted to C49.9: “Connective and other soft tissues, NOS” in ICD-10 (see ICD-10 Volume 2, page 74).
Theoretically, the use of a standard, well-designed coding system such as ICD should make the analysis and tabulation of comparable results a simple matter. But in practice, it has been a continual exercise in detection for the editors of CI5 to establish exactly how registries code various cancers. For the present volume, registries were asked whether any malignant diagnoses were excluded from their data, and how they coded intraductal carcinoma of breast, NOS; ductal and lobular carcinoma in situ of breast; ovarian cystadenoma of borderline malignancy; borderline tumour of ovary; benign tumours of brain and nervous system; and in situ and unspecified carcinoma of bladder.

Non-melanoma skin cancer
The incidence of non-melanoma skin cancer (NMSC) is difficult to assess. These cancers are very common and rarely fatal, and the completeness of their registration varies widely depending on access to outpatient and general practitioners’ records. Most NMSCs are basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs); other skin cancers are rare. Although some registries record the first occurrence of all NMSCs, others register BCC only , and many do not collect data on either SCC or BCC.

Bladder cancer
The issue of coding non-invasive tumours (taking into account the recorded level of invasion and grade) – and which to include in the tables as “cancer of the bladder” – has long been a subject of debate. In CI5 Volume VI, it was decided, for the sake of geographical comparability, to exclude tumours of benign, in situ, and unspecified behaviour. In principle, the availability of data as individual case listings with histological type and behaviour should make it possible to publish only data on malignant cancer, by excluding diagnoses with any behaviour code other than /3. But when registries were asked about the behaviour codes they used for non-invasive and unspecified diagnoses of malignant bladder cancer for Volume VII, many of them reported that they assigned the behaviour code /3 to both in situ and unspecified diagnoses, making it impossible to distinguish such cases. As a result, the editors decided to accept that non-invasive diagnoses of bladder cancer are generally considered malignant by pathologists; since Volume VII, the bladder cancer rubric (ICD-10 C67) has therefore included the in situ (ICD 10 D09.0) and unspecified (ICD 10 D41.4) categories. In this volume, whenever possible, the inclusion of neoplasms of uncertain or unknown behaviour together with invasive cancers is indicated by a dagger symbol beside C67 in the tables, and a note on the data in the accompanying narrative. A few registries preferred not to include such cases in their dataset, even when available in the registry, for the sake of continuity over time.

Breast cancer
Intraductal carcinoma, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ of breast are classified in ICD-O-3 as in situ cancers (behaviour code /2). All the registries in CI5 Volume XI collect these diagnoses.

Ovarian cancer
The registries contributing to this volume were asked how they coded ovarian cystadenoma of borderline malignancy and borderline tumour of ovary. Borderline ovarian diagnoses are classified as non-malignant tumours in ICD-O-3 (behaviour code /1) and are excluded from the tabulations, but a few registries still code them as malignant neoplasms.

Brain and central nervous system
Many registries choose to include benign and unspecified tumours of the brain and central nervous system in their data, because of the potentially serious clinical consequences of these tumours. Prior to Volume VII, such tumours may therefore have been included in the tables along with cancers of the brain and nervous system. However, the proportion of such cases varies widely between registries, so since Volume VII they are no longer included.

Myeloproliferative disorders and myelodysplastic syndromes
These include records with the ICD-O-3 morphological codes 9950/3, 996_/3, 9971/3, 9975/3, 998_/3 and 999_/3. Only registries that originally coded their data to ICD-O-3 can report such diagnoses, as they were not considered malignant tumours in ICD-O-2 (behaviour code /1). These codes are converted to the ICD-10 codes D45, D46_, and D47_ by the IARC ICD O-3 to ICD-10 conversion program (except M9966/3, M9967/3 and M9984/3 which are converted to ICD-10 C92.7, C96.7 and C92.0 respectively, see Table 3.2), and are presented in two separate categories in the tables “Myeloproliferative disorders (MPD)” and “Myelodysplastic syndromes (MDS)” and also included in the “All sites (C00-96)” category.

Table 3.1. Classification used in the incidence tables in CI5 Volume XI
ICD-10 (version 2010) site codeFull ICD-10 titleGrouping used in tablesShort title used in tables
C00Malignant neoplasm of lipLip
C01Malignant neoplasm of base of tongueC01–C02 are groupedTongue
C02Malignant neoplasm of other and unspecified parts of tongue
C03Malignant neoplasm of gumC03–C06 are groupedMouth
C04Malignant neoplasm of floor of mouth
C05Malignant neoplasm of palate
C06Malignant neoplasm of other and unspecified parts of mouth
C07Malignant neoplasm of parotid glandC07–C08 are groupedSalivary gland
C08Malignant neoplasm of other and unspecified major salivary glands
C09Malignant neoplasm of tonsilTonsil
C10Malignant neoplasm of oropharynxOther oropharynx
C11Malignant neoplasm of nasopharynxNasopharynx
C12Malignant neoplasm of pyriform sinusC12–C13 are groupedHypopharynx
C13Malignant neoplasm of hypopharynx
C14Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynxPharynx unspecified
C15Malignant neoplasm of oesophagusOesophagus
C16Malignant neoplasm of stomachStomach
C17Malignant neoplasm of small intestineSmall intestine
C18Malignant neoplasm of colonColon
C19Malignant neoplasm of rectosigmoid junctionC19–C20 are groupedRectum
C20Malignant neoplasm of rectum
C21Malignant neoplasm of anus and anal canalAnus
C22Malignant neoplasm of liver and intrahepatic bile ductsLiver
C23Malignant neoplasm of gallbladderC23–C24 are groupedGallbladder etc.
C24Malignant neoplasm of other and unspecified parts of biliary tract
C25Malignant neoplasm of pancreasPancreas
C26Malignant neoplasm of other and ill-defined digestive organsC26 is included in other and unspecified malignant neoplasms
C30Malignant neoplasm of nasal cavity and middle earC30–C31 are groupedNose, sinuses, etc.
C31Malignant neoplasm of accessory sinuses
C32Malignant neoplasm of larynxLarynx
C33Malignant neoplasm of tracheaC33–C34 are groupedTrachea, bronchus, and lung
C34Malignant neoplasm of bronchus and lung
C37Malignant neoplasm of thymusC37–C38 are groupedOther thoracic organs
C38Malignant neoplasm of heart, mediastinum and pleura
C39Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organsC39 is included in other and unspecified malignant neoplasms
C40Malignant neoplasm of bone and articular cartilage of limbsC40–C41 are groupedBone
C41Malignant neoplasm of bone and articular cartilage of other and unspecified sites
C43Malignant melanoma of skinMelanoma of skin
C44Other malignant neoplasms of skinOther skin
C46Kaposi sarcomaKaposi sarcoma
C47Malignant neoplasm of peripheral nerves and autonomic nervous systemC47 is grouped with C49Connective and soft tissue
C48Malignant neoplasm of retroperitoneum and peritoneumC48 is included in other and unspecified malignant neoplasms
C49Malignant neoplasm of other connective and soft tissueC49 is grouped with C47
C50Malignant neoplasm of breastBreast
C51Malignant neoplasm of vulvaVulva
C52Malignant neoplasm of vaginaVagina
C53Malignant neoplasm of cervix uteriCervix uteri
C54Malignant neoplasm of corpus uteriCorpus uteri
C55Malignant neoplasm of uterus, part unspecifiedUterus unspecified
C56Malignant neoplasm of ovaryOvary
C57Malignant neoplasm of other and unspecified female genital organsOther female genital organs
C58Malignant neoplasm of placentaPlacenta
C60Malignant neoplasm of penisPenis
C61Malignant neoplasm of prostateProstate
C62Malignant neoplasm of testisTestis
C63Malignant neoplasm of other and unspecified male genital organsOther male genital organs
C64Malignant neoplasm of kidney, except renal pelvisKidney
C65Malignant neoplasm of renal pelvisRenal pelvis
C66Malignant neoplasm of ureterUreter
C67Malignant neoplasm of bladderBladder
C68Malignant neoplasm of other and unspecified urinary organsOther urinary organs
C69Malignant neoplasm of eye and adnexaEye
C70Malignant neoplasm of meningesC70–C72 are groupedBrain and nervous system
C71Malignant neoplasm of brain
C72Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system
C73Malignant neoplasm of thyroid glandThyroid
C74Malignant neoplasm of adrenal glandAdrenal gland
C75Malignant neoplasm of other endocrine glands and related structuresOther endocrine
C76Malignant neoplasm of other and ill-defined sitesC76 is included in other and unspecified malignant neoplasms
C80Malignant neoplasm, without specification of siteC80 is included in other and unspecified malignant neoplasms
C81Hodgkin lymphomaHodgkin lymphoma
C82Follicular lymphomaC82–C86 and C96 are groupedNon-Hodgkin lymphoma
C83Non-Follicular lymphoma
C84Mature T/NK-cell lymphomas
C85Other and unspecified types of non-Hodgkin lymphoma
C86Other specified types of T/NK-cell lymphoma
C88Malignant immunoproliferative diseasesImmunoproliferative diseases
C90Multiple myeloma and malignant plasma cell neoplasmsMultiple myeloma
C91Lymphoid leukaemiaLymphoid leukaemia
C92Myeloid leukaemiaC92–C94 are grouped (following ICD-O-3)Myeloid leukaemia
C93Monocytic leukaemia
C94Other leukaemias of specified cell type
C95Leukaemia of unspecified cell typeLeukaemia unspecified
C96Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissueC96 is grouped with C82–C86
O&UOther and unspecified malignant neoplasmsIncludes C26, C39, C48, C76, and C80Other and unspecified
MPDMyeloproliferative disordersIncludes ICD-O-3 M9950/3, M9960-M9965/3, M9971/3 and M9975/3Myeloproliferative disorders
MDSMyelodysplastic syndromesIncludes ICD-O-3 M9980-9983/3,M9985-9989/3, M9991/3 and M9992/3Myelodysplastic syndromes
C00-96*All sites
C00-96* exc. C44All sites except C44
*Includes O&U, MPD and MDS site codes

Table 3.2. Conversion of lymphoid and haematopoietic diseases (ICD-O-3 M9590-M9992)
ICD-O-3 (first revision) codeFull ICD-O-3 titleICD-10 (version 2010) site code
Malignant lymphomas, NOS or diffuse
9590/3Malignant lymphoma, NOSC85.9
9591/3Malignant lymphoma, non-Hodgkin, NOSC85.9
9596/3Composite Hodgkin and non-Hodgkin lymphomaC85.1
9597/3Primary cutaneous follicle centre lymphomaC82.6
Hodgkin lymphoma
9650/3Hodgkin lymphoma, NOSC81.9
9651/3Hodgkin lymphoma, lymphocyte-richC81.4
9652/3Hodgkin lymphoma, mixed cellularity, NOSC81.2
9653/3Hodgkin lymphoma, lymphocyte depletion, NOSC81.3
9654/3Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosisC81.3
9655/3Hodgkin lymphoma, lymphocyte depletion, reticularC81.3
9659/3Hodgkin lymphoma, nodular lymphocyte predominanceC81.0
9661/3Hodgkin granulomaC81.9
9662/3Hodgkin sarcomaC81.3
9663/3Hodgkin lymphoma, nodular sclerosis, NOSC81.1
9664/3Hodgkin lymphoma, nodular sclerosis, cellular phaseC81.1
9665/3Hodgkin lymphoma, nodular sclerosis, grade 1C81.1
9667/3Hodgkin lymphoma, nodular sclerosis, grade 2C81.1
Mature B-cell lymphomas
9670/3Malignant lymphoma, small B lymphocytic, NOSC83.0
9671/3Malignant lymphoma, lymphoplasmacyticC83.0
9673/3Mantle cell lymphomaC83.1
9675/3Malignant lymphoma, mixed small and large cell, diffuseC85.9
9678/3Primary effusion lymphomaC83.8
9679/3Mediastinal large B-cell lymphoma (C38.3)C85.2
9680/3Malignant lymphoma, large B-cell, diffuse, NOSC83.3
9684/3Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOSC83.3
9687/3Burkitt lymphoma, NOSC83.7
9688/3T-cell/histiocyte rich large B-cell lymphomaC83.3
9689/3Splenic marginal zone B-cell lymphoma (C42.2)C83.0
9690/3Follicular lymphoma, NOSC82.9
9691/3Follicular lymphoma, grade 2C82.1
9695/3Follicular lymphoma, grade 1C82.0
9698/3Follicular lymphoma, grade 3C82.2
9699/3Marginal zone B-cell lymphoma, NOSC83.0 (C42.0; C42.1; C42.4, C77._)
C88.4 (other topography)
Mature T- and NK-cell lymphomas
9700/3Mycosis fungoides (C44._)C84.0
9701/3Sezary syndromeC84.1
9702/3Mature T-cell lymphoma, NOSC84.4
9705/3Angioimmunoblastic T-cell lymphomaC86.5
9708/3Subcutaneous panniculitis-like T-cell lymphomaC86.3
9709/3Cutaneous T-cell lymphoma, NOS (C44._)C84.8
9712/3Intravascular large B-cell lymphoma (C49.9)C83.8
9714/3Anaplastic large cell lymphoma, T cell and Null cell typeC84.6
9716/3Hepatosplenic T-cell lymphomaC86.1
9717/3Intestinal T-cell lymphomaC86.2
9718/3Primary cutaneous CD30+ T-cell lymphoproliferative disorder (C44._)C86.6
9719/3NK/T-cell lymphoma, nasal and nasal-typeC86.0
Precursor cell lymphoblastic lymphoma
9724/3Systemic EBV positive T-cell lymphoproliferative disease of childhoodC84.5
9725/3Hydroa vacciniforme-like lymphomaC84.5
9726/3Primary cutaneous gamma-delta T-cell lymphomaC84.5
9727/3Precursor cell lymphoblastic lymphoma, NOSC83.5*
9728/3Precursor B-cell lymphoblastic lymphomaC83.5
9729/3Precursor T-cell lymphoblastic lymphomaC83.5
Plasma cell tumors
9731/3Plasmacytoma, NOSC90.3
9732/3Multiple myeloma (C42.1)C90.0
9733/3Plasma cell leukemia (C42.1)C90.1
9734/3Plasmacytoma, extramedullaryC90.2
9735/3Plasmablastic lymphomaC83.3
9737/3ALK positive large B-cell lymphomaC83.3
9738/3Large B-cell lymphoma arising in HHV8-associated multicentric Castleman diseaseC83.3
Mast cell tumors
9740/1Mastocytoma, NOSD47.0
9740/3Mast cell sarcomaC96.2
9741/1Indolent systemic mastocytosisD47.0
9741/3Malignant mastocytosisC96.2
9742/3Mast cell leukemia (C42.1)C94.3
Neoplasms of histiocytes and accessory lymphoid cells
9750/3Malignant histiocytosisC96.8
9751/3Langerhans cell histiocytosis, NOSC96.6
9755/3Histiocytic sarcomaC96.8
9756/3Langerhans cell sarcomaC96.4
9757/3Interdigitating dendritic cell sarcomaC96.4
9758/3Follicular dendritic cell sarcomaC96.4
9759/3Fibroblastic reticular cell tumorC96.4
Immunoproliferative diseases
9760/3Immunoproliferative disease, NOSC88.9
9761/3Waldenstrom macroglobulinemia (C42.0)C88.0
9762/3Heavy chain disease, NOSC88.2
9764/3Immunoproliferative small intestinal disease (C17._)C88.3
9765/1Monoclonal gammopathy of undetermined significanceD47.2
9766/1Angiocentric immunoproliferative lesionC83.8
9767/1Angioimmunoblastic lymphadenopathy (AIC)C86.5
9768/1T-gamma lymphoproliferative diseaseD47.9
9769/1Immunoglobulin deposition diseaseD47.7
Leukemias, NOS
9800/3Leukemia, NOSC95.9
9801/3Acute leukemia, NOSC95.0
9805/3Acute biphenotypic leukemiaC95.0
9806/3Mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1C95.0
9807/3Mixed phenotype acute leukemia with t(v;11q23);MLL rearrangedC95.0
9808/3Mixed phenotype acute leukemia, B/myeloid, NOSC95.0
9809/3Mixed phenotype acute leukemia, T/myeloid, NOSC95.0
Lymphoid leukemias
9811/3B lymphoblastic leukemia/lymphoma, NOSC91.0
9812/3B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2);BCR-ABL1C91.0
9813/3B lymphoblastic leukemia/lymphoma with t(v;11q23);MLL rearrangedC91.0
9814/3B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22);TEL-AML1 (ETV6-RUNX1)C91.0
9815/3B lymphoblastic leukemia/lymphoma with hyperdiploidyC91.0
9816/3B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL)C91.0
9817/3B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32);IL3-IGHC91.0
9818/3B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);E2A PBX1 (TCF3 PBX1)C91.0
9820/3Lymphoid leukemia, NOSC91.9
9823/3B-cell chronic lymphocytic leukemia/small lymphocytic lymphomaC91.1
9826/3Burkitt cell leukemiaC91.8
9827/3Adult T-cell leukemia/lymphoma (HTLV-1 positive)C91.5
9831/3T-cell large granular lymphocytic leukemiaC91.7
9832/3Prolymphocytic leukemia, NOSC91.3
9833/3Prolymphocytic leukemia, B-cell typeC91.3
9834/3Prolymphocytic leukemia, T-cell typeC91.6
9835/3Precursor cell lymphoblastic leukemia, NOSC91.0
9836/3Precursor B-cell lymphoblastic leukemiaC91.0
9837/3T lymphoblastic leukemia/lymphomaC91.0
Myeloid leukemias
9840/3Acute myeloid leukemia, M6 typeC94.0
9860/3Myeloid leukemia, NOSC92.9
9861/3Acute myeloid leukemia, NOSC92.0
9863/3Chronic myeloid leukemia, NOSC92.1
9865/3Acute myeloid leukemia with t(6;9)(p23;q34) DEK-NUP214C92.0
9866/3Acute promyelocytic leukemia, t(15;17)(q22;q11-12)C92.4
9867/3Acute myelomonocytic leukemiaC92.5
9869/3Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1C92.0
9870/3Acute basophilic leukemiaC94.7
9871/3Acute myeloid leukemia with abnormal marrow eosinophilsC92.5
9872/3Acute myeloid leukemia, minimal differentiationC92.0
9873/3Acute myeloid leukemia without maturationC92.0
9874/3Acute myeloid leukemia with maturationC92.0
9875/3Chronic myelogenous leukemia, BCR/ABL positiveC92.1
9876/3Atypical chronic myeloid leukemia, BCR/ABL negativeC92.2
9891/3Acute monocytic leukemiaC93.0
9895/3Acute myeloid leukemia with myelodysplasia-related changesC92.8
9896/3Acute myeloid leukemia, t(8;21)(q22;q22)C92.0
9897/3Acute myeloid leukemia, 11q23 abnormalitiesC92.6
9898/1Transient abnormal myelopoiesisD47.1
9898/3Myeloid leukemia associated with Down SyndromeC92.7
9910/3Acute megakaryoblastic leukemiaC94.2
9911/3Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1C94.2
9920/3Therapy related myeloid neoplasmC94.6
9930/3Myeloid sarcomaC92.3
9931/3Acute panmyelosis with myelofibrosis (C42.1)C94.4
9940/3Hairy cell leukemia (C42.1)C91.4
Other leukemias
9945/3Chronic myelomonocytic leukemia, NOSC93.1
9946/3Juvenile myelomonocytic leukemiaC93.3
9948/3Aggressive NK-cell leukemiaC94.7
Chronic myeloproliferative disorders
9950/3Polycythemia veraD45/MPD
9960/3Myeloproliferative neoplasm, NOSD47.1/MPD
9961/3Primary myelofibrosisD47.4/MPD
9962/3Essential thrombocythemiaD47.3/MPD
9963/3Chronic neutrophilic leukemiaD47.1/MPD
9964/3Chronic eosinophilic leukemia, NOSD47.5/MPD
9965/3Myeloid and lymphoid neoplasms with PDGFRA rearrangementD47.5/MPD
9966/3Myeloid neoplasms with PDGFRB rearrangementC92.7
9967/3Myeloid and lymphoid neoplasms with FGFR1 abnormalitiesC96.7
Other hematologic disorders
9971/3Polymorphic post transplant lymphoproliferative disorderD47.7/MPD
9975/3Myloproliferative neoplasm, unclassifiableD47.1/MPD
Myelodysplastic syndromes
9980/3Refractory anemiaD46.4/MDS
9982/3Refractory anemia with sideroblastsD46.1/MDS
9983/3Refractory anemia with excess blastsD46.2/MDS
9984/3Refractory anemia with excess blasts in transformationC92.0
9985/3Refractory cytopenia with multilineage dysplasiaD46.5/MDS
9986/3Myelodysplastic syndrome with 5q deletion (5q-) syndromeD46.6/MDS
9987/3Therapy-related myelodysplastic syndrome, NOSD46.7/MDS
9989/3Myelodysplastic syndrome, NOSD46.9/MDS
9991/3Refractory neutropeniaD46.7/MDS
9992/3Refractory thrombocytopeniaD46.7/MDS
*If used for “Blastic plasmacytoid dendritic cell neoplasm”, then convert to C86.4
#Normally coded with a behaviour code /1, but few cases were reported with a behaviour code /3